The short version of incretin fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-04. Anything still debated is marked as such rather than presented as settled.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
In stereochemistry, a torsion angle is defined as a particular example of a dihedral angle, describing the geometric relation of two parts of a molecule joined by a chemical bond. Every set of three non-colinear atoms of a molecule defines a half-plane. As explained above, when two such half-planes intersect (i.e., a set of four consecutively-bonded atoms), the angle between them is a dihedral angle. Dihedral angles are used to specify the molecular conformation. Stereochemical arrangements corresponding to angles between 0° and ±90° are called syn (s), those corresponding to angles between ±90° and 180° anti (a). Similarly, arrangements corresponding to angles between 30° and 150° or between −30° and −150° are called clinal (c) and those between 0° and ±30° or ±150° and 180° are called periplanar (p). The two types of terms can be combined so as to define four ranges of angle; 0° to ±30° synperiplanar (sp); 30° to 90° and −30° to −90° synclinal (sc); 90° to 150° and −90° to −150° anticlinal (ac); ±150° to 180° antiperiplanar (ap). The synperiplanar conformation is also known as the syn- or cis-conformation; antiperiplanar as anti or trans; and synclinal as gauche or skew. For example, with n-butane two planes can be specified in terms of the two central carbon atoms and either of the methyl carbon atoms. The syn-conformation shown above, with a dihedral angle of 60° is less stable than the anti-conformation with a dihedral angle of 180°. For macromolecular usage the symbols T, C, G+, G−, A+ and A− are recommended (ap, sp, +sc, −sc, +ac and −ac respectively).
Cleavage at the reactive site results in entrapment of the thrombin protease, with movement of the cleaved reactive site loop together with the bound protease, such that the loop forms an extra sixth strand in the middle of beta sheet A. This movement of the reactive site loop can also be induced without cleavage, with the resulting crystallographic structure being identical to that of the physiologically latent conformation of plasminogen activator inhibitor-1 (PAI-1). For this reason the conformation of antithrombin in which the reactive site loop is incorporated uncleaved into the main body of the protein is referred to as latent antithrombin. In contrast to PAI-1 the transition for antithrombin from a normal or native conformation to a latent conformation is irreversible. Native antithrombin can be converted to latent antithrombin (L-antithrombin) by heating alone or heating in the presence of citrate. However, without extreme heating and at 37 °C (body temperature) 10% of all antithrombin circulating in the blood is converted to the L-antithrombin over a 24-hour period. The structure of L-antithrombin is shown in Figure 6. The 3-dimensional structure of native antithrombin was first determined in 1994. Unexpectedly the protein crystallized as a heterodimer composed of one molecule of native antithrombin and one molecule of latent antithrombin.
== Evolutionary conservation == SMN is evolutionarily conserved including the Fungi kingdom, though only fungal organisms with a great number of introns have the Smn gene (or the splicing factor spf30 paralogue). Surprisingly, these are filamentous fungus which have mycelia, so suggesting analogy to the neuronal axons.
James is swept into the Shadow Realm and sees a partygoer being attacked seconds before she collapses in the real world. The day after, Cordelia takes James aside and he reveals his relationship with Grace to her. Cordelia is heartbroken but happy for him. A demon attack wounds Ariadne Bridgestock and Barbara Lightwood, Thomas's oldest sister. In a flashback, James meets Grace once again. She points out that he was in love with Cordelia, which he half-heartedly denied. Later on, Grace requested him to use his shadow abilities to retrieve her Cartwright familial bracelet which Tatiana seized. A demon kept in Tatiana's greenhouse destroys it, and she blames James. Later, James reads a missive addressed to Matthew, signed by Grace. James immediately goes out alone. Jesse visits Lucie in her bedroom and informs her that James is in danger, as Grace was being followed by the Blackthorn family demon and would probably murder anyone who wasn't a Blackthorn. She goes to save James. Cordelia, Matthew and Anna Lightwood (Christopher's older sister) visit Malcolm Fade and Hypatia Vex, where they inquire about the attacks and if the downworlders might have heard of it. Cordelia saves the warlocks' lives, and in return they send for Ragnor Fell who might be able to help Cordelia. In a flashback to 1902, Thomas Lightwood had been gone for his travel year and stopped at Paris. He had met Alastair Carstairs there, and they had toured the whole city amiably. Around that time, Thomas had felt himself warming up to Alastair.
Sources: en.wikipedia.org
=== Evaluation === The thyroid is examined by observation of the gland and surrounding neck for swelling or enlargement. It is then felt, usually from behind, and a person is often asked to swallow to better feel the gland against the fingers of the examiner. The gland moves up and down with swallowing because of its attachments to the thyroid and cricoid cartilages. In a healthy person the gland is not visible yet is palpable as a soft mass. Examination of the thyroid gland includes the search for abnormal masses and the assessment of overall thyroid size. The character of the thyroid, swellings, nodules, and their consistency may all be able to be felt. If a goitre is present, an examiner may also feel down the neck consider tapping the upper part of the chest to check for extension. Further tests may include raising the arms (Pemberton's sign), listening to the gland with a stethoscope for bruits, testing of reflexes, and palpation of the lymph nodes in the head and neck. An examination of the thyroid will also include observation of the person as a whole, to look for systemic signs such as weight gain or loss, hair loss, and signs in other locations – such as protrusion of the eyes or swelling of the calves in Graves' disease.
Arguing in favour of independence, President Mangope claimed that the move would enable its population to negotiate with Pretoria from a stronger position: "We would rather face the difficulties of administering a fragmented territory, the wrath of the outside world, and accusations of ill-informed people. It's the price we are prepared to pay for being masters of our own destiny." United Nations Secretary-General Kurt Waldheim stated that he "strongly deplored" the establishment of "another so-called independent tribal homeland in pursuance of the discredited policies of apartheid", and in resolution A/RES/32/105N, passed on 14 December 1977, the United Nations General Assembly linked Bophuthatswana's "so-called 'independence'" to South Africa's "stubborn pursuit" of its policies, and called upon all governments to "deny any form of recognition to the so-called 'independent' bantustans". During a parliamentary debate in the UK on 6 December 1977, Foreign Secretary David Owen replied in the negative when asked "whether Her Majesty's Government intend to recognise travel documents issued by the authorities of ... Bophuthatswana for the purpose of admitting visitors to the United Kingdom". While the majority of news reports echoed these official declarations, there were others which opined that Western critics should "suspend judgment for a time", and despite its generally critical stance on South Africa's policies, Time magazine wrote that Bophuthatswana had "considerable economic potential" with an expected $30 million a year coming from mining revenues.
=== Twentieth century === Beak trimming was developed at the Ohio Agricultural Experiment Station in the 1930s. The original technique was temporary, cutting approximately 6 mm (1/4 inch) off the beak. It was thought that the tip of the beak had no blood supply and presumably no sensation. The procedure was performed by hand with a sharp knife, either when deaths due to cannibalism became excessive, or when the problem was anticipated because of a history of cannibalism in the particular strain of chicken. Cannibalism is a serious management problem dating back to the periods before intensive housing of poultry became popular. Poultry books written before vertical integration of the poultry industry describe the abnormal pecking of poultry:
The two substrates of this enzyme are 4-phospho-D-erythronic acid and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are (R)-3-hydroxy-2-oxo-4-phosphonooxybutanoic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 4-phospho-D-erythronate:NAD+ 2-oxidoreductase. Other names in common use include PdxB, PdxB 4PE dehydrogenase, and 4-O-phosphoerythronate dehydrogenase. This enzyme participates in vitamin B6 metabolism.
Americium (95Am) is an artificial element, and thus a standard atomic weight cannot be given. Like all artificial elements, it has no known stable isotopes. The first isotope to be synthesized was 241Am in 1944. The artificial element decays by ejecting alpha particles. Americium has an atomic number of 95 (the number of protons in the nucleus of the americium atom). Despite 243Am being an order of magnitude longer lived than 241Am, the former is harder to obtain than the latter as more of it is present in spent nuclear fuel. Nineteen radioisotopes of americium, ranging from 229Am to 247Am have been characterized; another isotope, 223Am, has also been reported but is unconfirmed. The most stable isotopes are 243Am with a half-life of 7,350 years and 241Am with a half-life of 432.6 years. All of the remaining radioactive isotopes have half-lives that are less than seven days, the majority of which are shorter than two hours. This element also has fourteen meta states, with the most stable being 242m1Am (half-life 141 years). This isomer is unusual in that its half-life is far longer than that of the ground state of the same isotope.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.